De Soto, KS, United States
De Soto, KS, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Oncimmune | Date: 2015-06-19

The present invention generally relates to the field of antibody detection, and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid. The invention provides a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein the test sample is contacted with a plurality of different amounts of an antigen specific for the antibody, the amount of specific binding between the antibody and the antigen is detected and the presence or absence of antibody is determined based upon the amount of specific binding between the antibody and the antigen and a secondary curve parameter arising from a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used.


Patent
Oncimmune | Date: 2017-04-26

The present invention generally relates to the field of antibody detection, and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid. The invention provides a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein the test sample is contacted with a plurality of different amounts of an antigen specific for the antibody, the amount of specific binding between the antibody and the antigen is detected and the presence or absence of antibody is determined based upon the amount of specific binding between the antibody and the antigen and a secondary curve parameter arising from a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used.


Patent
Oncimmune | Date: 2016-09-23

The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.


Patent
Oncimmune | Date: 2012-04-25

The invention generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.


Patent
Oncimmune | Date: 2013-09-24

The application generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.


Patent
Oncimmune | Date: 2011-01-19

The invention generally relats to the field of diagnostic or prognostic assays. In particular, the invention provides a method of determining an antibody profile in a test sample comprising a bodily fluid from a mammalian subject, wherein the antibody is a biological marker of a disease state or disease susceptibility.


Patent
Oncimmune | Date: 2014-04-07

The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.


Patent
Oncimmune | Date: 2014-04-07

The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.


Oncimmune, a leader in early cancer detection, today announced the appointment of Meinhard Schmidt as Non-Executive Chairman. Meinhard has more than 25 years international experience as an entrepreneur and senior executive in the diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, program and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at Sphere Medical PLC, valuationLAB AG, CeQur AG and as Chairman at Promimic AB. Meinhard Schmidt, said: "The early detection of cancer can transform outcomes for patients. Oncimmune's EarlyCDT® technology has an excellent scientific pedigree, has been extensively validated and EarlyCDT®-Lung is already on the market in the US, UK and other territories. With the prospect of building on the technology platform to expand into additional cancer types and reach new markets, Oncimmune is poised for growth and I'm very pleased to become Chairman at this exciting time in the Company's development." Geoffrey Hamilton-Fairley, CEO of Oncimmune Limited, said: "It is a great pleasure to welcome Meinhard as Chairman of Oncimmune. His industry experience is exceptional and I very much look forward to working with him as we accelerate the next stage in the Company's development, namely the further commercialisation of EarlyCDT®-Lung on a global basis and the launch of our new EarlyCDT® cancer tests. Meinhard's commercial expertise will enable us to realise the potential of our pioneering autoantibody approach to cancer detection." EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results showing a cancer detection rate of 81%, better than the stated test performance, were recently presented at the 16th World Conference on Lung Cancer. Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and be applied to a very wide range of solid tumour types. The Company's proprietary EarlyCDT® technology platform was launched in 2009 and EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT® tests for liver and ovarian cancer are in final validation. Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.


Loading Oncimmune collaborators
Loading Oncimmune collaborators